Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2016/2490168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556158142906368 |
|---|---|
| author | Muhammad Husnain Sandra Kurtin Nikki Barkett Irbaz bin Riaz Amit Agarwal |
| author_facet | Muhammad Husnain Sandra Kurtin Nikki Barkett Irbaz bin Riaz Amit Agarwal |
| author_sort | Muhammad Husnain |
| collection | DOAJ |
| description | Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the first-in-class human monoclonal antibody against CD38 cells which was studied in phase I/II trials for treatment of these patients with relapsed refractory multiple myeloma. It showed an overall response rate of 36% and a median overall survival (OS) of 17 months in these patients. We report a case of 40-year-old man with immunoglobulin D (IgD) multiple myeloma whose disease was refractory to at least 5 different chemotherapy regimens including proteasome inhibitors and immunomodulatory drugs. The clinical studies assessing daratumumab did not include any patients with IgD myeloma which is a rare form of multiple myeloma and to our knowledge is the first study reporting use of daratumumab in IgD myeloma. |
| format | Article |
| id | doaj-art-bc61fb07e4f64a7cb62327fe027cdbd7 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-bc61fb07e4f64a7cb62327fe027cdbd72025-02-03T05:46:14ZengWileyCase Reports in Oncological Medicine2090-67062090-67142016-01-01201610.1155/2016/24901682490168Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature ReviewMuhammad Husnain0Sandra Kurtin1Nikki Barkett2Irbaz bin Riaz3Amit Agarwal4Department of Medicine, University of Arizona, Tucson, AZ, USABanner University Medical Center Tucson, Department of Hematology Oncology, University of Arizona, Tucson, AZ, USABanner University Medical Center Tucson, Department of Hematology Oncology, University of Arizona, Tucson, AZ, USADepartment of Medicine, University of Arizona, Tucson, AZ, USADepartment of Medicine, University of Arizona, Tucson, AZ, USAPatients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the first-in-class human monoclonal antibody against CD38 cells which was studied in phase I/II trials for treatment of these patients with relapsed refractory multiple myeloma. It showed an overall response rate of 36% and a median overall survival (OS) of 17 months in these patients. We report a case of 40-year-old man with immunoglobulin D (IgD) multiple myeloma whose disease was refractory to at least 5 different chemotherapy regimens including proteasome inhibitors and immunomodulatory drugs. The clinical studies assessing daratumumab did not include any patients with IgD myeloma which is a rare form of multiple myeloma and to our knowledge is the first study reporting use of daratumumab in IgD myeloma.http://dx.doi.org/10.1155/2016/2490168 |
| spellingShingle | Muhammad Husnain Sandra Kurtin Nikki Barkett Irbaz bin Riaz Amit Agarwal Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review Case Reports in Oncological Medicine |
| title | Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review |
| title_full | Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review |
| title_fullStr | Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review |
| title_full_unstemmed | Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review |
| title_short | Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review |
| title_sort | refractory igd multiple myeloma treated with daratumumab a case report and literature review |
| url | http://dx.doi.org/10.1155/2016/2490168 |
| work_keys_str_mv | AT muhammadhusnain refractoryigdmultiplemyelomatreatedwithdaratumumabacasereportandliteraturereview AT sandrakurtin refractoryigdmultiplemyelomatreatedwithdaratumumabacasereportandliteraturereview AT nikkibarkett refractoryigdmultiplemyelomatreatedwithdaratumumabacasereportandliteraturereview AT irbazbinriaz refractoryigdmultiplemyelomatreatedwithdaratumumabacasereportandliteraturereview AT amitagarwal refractoryigdmultiplemyelomatreatedwithdaratumumabacasereportandliteraturereview |